Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Covance, a provider of drug R&D services, has created a new Discovery & Translational Services group, which is expected to integrate its discovery services, antibody products and immunology services, Biomarker Center of Excellence, and Genomics Laboratory.
Subscribe to our email newsletter
Covance has appointed Jonathan Koch as vice president and general manager of Discovery & Translational Services.
Covance said that Discovery & Translational Services will report to Deborah Tanner, corporate senior vice president at Covance; president of Central Laboratory Services and president of Discovery & Translational Services.
Ms Tanner said: “By uniting our discovery and translational services under one operating umbrella we can better leverage current capabilities, foster greater scientific and technical collaboration, and ultimately provide greater value to our clients through a portfolio of services that parallel their drug development model.”
Joe Herring, chairman and CEO of Covance, said: “Increasingly our clients are looking for drug development companies that can provide a full spectrum of services and expertise from early drug discovery through late-stage clinical trials and post-marketing surveillance.
“Through a series of strategic investments and alliances, we have enhanced our early-stage drug R&D capabilities and gained an impressive array of talent and technologies in genomics, proteomics, biomarkers, and discovery services such as early safety and efficacy testing, in-vivo pharmacology and imaging.
“As a result, Covance now has a comprehensive range of integrated services across the drug R&D continuum that can help clients make faster and more effective decisions about their portfolios.”